STOCK TITAN
  1. Home
  2. Sec-filings
  3. AAPG
  4. [6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer)

Ascentage Pharma (AAPG) corrects AGM date for RSU and option schemes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Ascentage Pharma Group International clarifies the reference date used for its equity incentive plans. The company states that the annual general meeting at which the Scheme Mandate Limit applies to the 2021 Awards, 2022 Awards and Options is May 19, 2025, rather than May 20, 2026.

This update relates to the further grants of RSUs under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme announced on June 29, 2026. All other terms and information from that earlier announcement remain unchanged and continue to apply.

Positive

  • None.

Negative

  • None.
AGM date for Scheme Mandate Limit May 19, 2025 Annual general meeting whose Scheme Mandate Limit applies to 2021 Awards, 2022 Awards and Options
Previously referenced AGM date May 20, 2026 Date replaced by May 19, 2025 as the relevant AGM for the Scheme Mandate Limit
Original grant announcement date June 29, 2026 Date of announcement on further grants of RSUs and Options
Update announcement date July 13, 2026 Date of clarification regarding the AGM linked to the Scheme Mandate Limit
Scheme Mandate Limit regulatory
"the Scheme Mandate Limit pursuant to which the 2021 Awards, 2022 Awards and Options"
2021 RSU Scheme financial
"further grant of RSUs under the 2021 RSU Scheme and the 2022 RSU Scheme"
2022 RSU Scheme financial
"further grant of RSUs under the 2021 RSU Scheme and the 2022 RSU Scheme"
Post IPO Share Option Scheme financial
"further grant of Options under the Post IPO Share Option Scheme"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What does Ascentage Pharma (AAPG) clarify in the July 13, 2026 update?
Ascentage Pharma clarifies the AGM date tied to its Scheme Mandate Limit is May 19, 2025. The change confirms which shareholder approval supports satisfying the 2021 Awards, 2022 Awards and Options, without altering any other terms of the previously disclosed grants.

Which incentive plans of Ascentage Pharma (AAPG) are affected by this clarification?
The clarification affects the 2021 RSU Scheme, the 2022 RSU Scheme and the Post IPO Share Option Scheme. It confirms that awards and options under these plans rely on the Scheme Mandate Limit approved at the May 19, 2025 annual general meeting.

How does the corrected AGM date affect the Scheme Mandate Limit for AAPG?
The Scheme Mandate Limit is now explicitly linked to the AGM held on May 19, 2025. This defines the shareholder authorization under which the 2021 Awards, 2022 Awards and Options may be satisfied, replacing the previously referenced date of May 20, 2026.

Does Ascentage Pharma (AAPG) change any grant terms in this announcement?
No, the company states that all information in the June 29, 2026 announcement remains unchanged. Only the AGM date connected to the Scheme Mandate Limit is clarified, and all other grant details and conditions continue to apply as originally described.

When were Ascentage Pharma’s original and updated announcements on the grants released?
The company first described the further grant of RSUs and options on June 29, 2026. It then issued an update dated July 13, 2026 to clarify that the relevant AGM for the Scheme Mandate Limit was held on May 19, 2025.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

  

 

 

 

 

 

EXPLANATORY NOTE

 

On July 13, 2026, Ascentage Pharma Group International issued the announcement: “Update on The Further Grant Of Awards Under The 2021 RSU Scheme And The 2022 RSU Scheme; And Further Grant Of Options Under The Post IPO Share Option Scheme”. A copy of the announcement is furnished as Exhibit 99.1.

 

1

 

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Exhibit Title
     
99.1   Announcement dated July 13, 2026

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: July 13, 2026 /s/ Dajun Yang
  Name: Dajun Yang
  Title: Chief Executive Officer

 

3

Exhibit 99.1

 

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

 

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

 

UPDATE ON THE

FURTHER GRANT OF AWARDS UNDER

THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER

THE POST IPO SHARE OPTION SCHEME

 

Reference is made to the announcement of Ascentage Pharma Group International (the “Company”) dated June 29, 2026 in connection with the further grant of RSUs under the 2021 RSU Scheme and the 2022 RSU Scheme, as well as the further grant of Options under the Post IPO Share Option Scheme (the “Announcement”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

 

The Company would like to provide an update that, for the avoidance of doubt, the date of the annual general meeting of the Company at which the Scheme Mandate Limit pursuant to which the 2021 Awards, 2022 Awards and Options would be satisfied is May 19, 2025 as opposed to May 20, 2026.

 

Save as disclosed above, all other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is an update to and should be read in conjunction with the Announcement.

 

 By order of the Board
 Ascentage Pharma Group International Dr. Yang Dajun
 Chairman and Executive Director

 

Suzhou, the PRC, July 13, 2026

 

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote 1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note 2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

 

Notes:

 

1.Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

 

2.Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases